IMGN - Earnings call transcript Q4 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to ImmunoGen’s Fourth Quarter and Full Year 2020 Financial and Operating Results Conference call. Today’s conference is being recorded. At this time, I would like to turn the call over to Courtney O’Konek, Senior Director of Corporate Communications and Investor Relations. Please go ahead.

Courtney O’Konek

Good morning and thank you for joining today’s call. a progress that full and financial issued of a year we results. recent our fourth today, press includes release summary XXXX Earlier quarter and found of release our of immunogen.com. call a press at Investors recording This can Media and website be under section the and this With are our Mark President Berkenblit, CEO; Anna CFO. me Chief Altschuller, Medical our today our Officer; Enyedy, and and Susan

upcoming will over financial we call, review events. highlight the results XX today’s for business key During the our last months, and anticipated accomplishments

During materially Descriptions statements associated may risks call the And ImmunoGen use our and filings. that, forward-looking uncertainties SEC in with discussion, we the from over will I are to actual results our turn included with and of Mark. differ an investment statements. in such the will

Mark Enyedy

and positioned these morning, new and today. points, management year, portfolio, program, on working, of few our was a product the a for joining Good challenges the as cancer. just with Courtney. to ImmunoGen sheet ways our next to ovarian for you everyone potential two team mirvetuximab we pandemic, us of thank beginning lead adjusted of launches transformative XXXX strengthened for the Despite expand our Thanks, business balance in advanced year and

combination submit by into end for expect lines to last initial program With each patients approval expand line an XXXX. obtain to XXXX year and third of of our As support in a reminder, therapy our the we goals the We the as in deliver in earlier on approval progress in monotherapy these top emphasis BLA to this regimens. significant and objectives this accelerated program, monotherapy are to towards to with disease results with made of platinum-resistant year. over the quarter

has and call. ovarian choice we combination will presented cancer. both both platinum-sensitive cover these serve potential demonstrating last ESMO year, more studies, ASCO platinum-resistant detail that in For the agent the at data of in and results the in impressive mirvetuximab to combination our as Anna later

the the potential to thus With in we proximity approval. of benefit for generated monotherapy mirvetuximab believe of close far, initial the data to obtain listings use our combination compendia there is

with second We to is its therapy increase in BPDCN. IMGNXXX, treatment XXX full have which encouraging the path Updated profile our were potential in to presented and in patients quarter align we anti-tumor with on data favorable pivotal patients pleased relapsed/refractory with ADC. designation to our become the receive seen with confidence potential CDXXX-targeting to a the our Turning demonstrated fourth support breakthrough and to and BPDCN. clinic the approval ASH safety at for in best-in-class FDA XXXX program, activity in option BPDCN

recently start Huadong with agreement to and Huadong notable a in Medicine strategy FR is the A with receiving is strong the innovation with a an commercialize key to we China. which X XXXX China our In made are IND which application November, In into patient directed with mirvetuximab from of alpha IMGNXXX MacroGenics. integrates co-developing ADCs. enrolled Phase addition to each tumors. escalation development. preclinical a late-stage our mirvetuximab expressed acceptance collaboration innovative we novel This for cancer. of first-in-class ovarian to where ADC, types develop partnering Greater additional patient of pipeline solid into study the with in target next-generation off to In NMPA. allow XXX a populations the IMGCXXX, lower of dose including ADC ADC, anti-FR progress in we of wide on the tandem, two advanced should is range us our includes portfolio, tumor components of first of three XXX of our which in address levels expression, outside we is element alpha ADAMX, our

Finally, our facility, ATM the million sheet we through more added fourth under in business than to of $XXX our activity balance a and quarter. combination development

milestones. On ahead the strength important year of our performance in XXXX, about excited we several with are the

mentioned expect quarter, As to mirvetuximab, by earlier for line the data the year. in end a for the by SORAYA top we followed in the of report call, third submission I

cancer data We recurrent combination in FORWARD also bevacizumab anticipate evaluating sharing with final June. II from doublet in cohort the mirvetuximab in ASCO ovarian at

BPDCN for expect we XX XX to line and pivotal data the complete Phase IMGNXXX, For cohort our top months. enrollment X/X share in study frontline to in

plan to evaluating and IMGNXXX AML combination ASH. relapsed/refractory our in with with at and/or also report regimens We frontline patients data azacitidine from venetoclax

will study patients we to in or dose IMGCXXX, plan for early we submit IMGNXXX, the X Phase initial the year data by enroll And late this year continue For end. IND escalation to anticipate and next.

full with a of Anna Anna? look the to we So a provide will XXXX. events, that, calendar some forward important color With to call productive turn to over our programs. on clinical I additional

Anna Berkenblit

Thanks Mark.

and milestones mirvetuximab our monotherapy upcoming program. progress We have ongoing for covered the

doublet this Phase with presented my our studies. an oral in XXXX. cancer II will data ovarian mirvetuximab So platinum-agnostic FORWARD we comments efficacy recurrent the combination, of in to direct Xb safety ASCO bevacizumab and the from morning plus combination I Starting our session initial at study

and with recurrent status of encouraged with population in evaluation continued overall XX% be are by forward high response growing appropriate. We would platinum bevacizumab regimen non-platinum-based the FR whom a ovarian of particularly rate regardless observed the patients alpha look patients this mirvetuximab to of of cancer in expression for

year. data this this As present Mark to ASCO plan we from at mature study mentioned,

patients as levels a observed bevacizumab triplet We inhibitors duration data a of in FORWARD XXXX. cohort cohort, prior triplet carboplatin folate recurrent more of trials more also with XX% survival well or of median confirmed a is PARP patients with XX.X we percent with as median of more previously line as cancer. noteworthy therapies, and pretreated are prior of platinum-sensitive published progression-free therapy presented in XX.X including of than at mirvetuximab in this high efficacy of ovarian population having months the ESMO II receptor our than from of bevacizumab medium These combination rate overall heavily months. greater response targeted enrolled alpha, had response a one final evaluating with and data In and

Going XXX for tolerability, study will forward, favorable the data XX-patient trials encouraging doublet promise show of in year, in Phase wealth carboplatin X efficacy patients combination. about continues a cancer Having this to of investigator-sponsored mirvetuximab plus study. two supporting generate recurrent be randomized to generated we and a data mirvetuximab demonstrating a neoadjuvant ovarian and additional platinum-sensitive

listings approval, we mirvetuximab. label to initial In for potential a expansion path addition formal for with the to contemporaneous compendia define working to mirvetuximab’s are

to with BPDCN FDA, we in alignment patients XX Phase up having BPDCN path are study full approval on IMGNXXX, enrolling in to cohort the Moving received of frontline designation breakthrough in the and X/X IMGNXXX of a to pivotal complete and complete frontline and meet all XX of have data and Notably, clinical eligibility enrollment in expect X enrolled XX generate line patients. observed months. the to we criteria have top responses to patients who X these previously in

This BPDCN. rate activity of patients prior in These tagraxofusp-erzs. response intensive data patients. in overall patients, and these including an Phase relapsed/refractory who in prospective all XX% presented who in the At patients last we of patients are unable efficacy particularly for XX demonstrated IMGNXXX our received X/X towards data therapy, these are received IMGNXXX, those ASH demonstrates encouraging. relapsed/refractory findings updated While the count potential of we cohort prior safety from study to December year, with

hospitalization leak is without for once favorable or a weeks discontinuations Importantly, need mortality with it X without brief rate. administration. safety IMGNXXX deaths profile X% infusion has drug-related tolerated as and a capillary every for a syndrome, XX-day drug-related Accordingly, well outpatient initial

synergistic CDXXX-targeting care Taken in of presented as demonstrated models, of of ADC further standard relapsed/refractory data novel option together, lines addition AML to efficacy overcome patient-derived data this Also with the for a both with at the at potential IMGNXXX CDXXX Center Cancer anti-leukemia Anderson Vidaza These AML. and doublet convenience DNA that of ASH, with monotherapy. a MD support treatment best-in-class the safety, ADC the damaging the to cell AML of and support and potential BPDCN Vidaza resistance venetoclax. xenograft IMGNXXX a a azacitidine our In over patients. and to in further preclinical payload cell death the combination IMGNXXX collaborators triplet and targeted activity superior as has reinforce

dose to Our tolerability of safety, relapsed and azacitidine leukemia in combinations. and X CDXXX frontline in is AML. designed in enrolling combination IMGNXXX Phase is XXX phase the recommended patients determine Phase of to activity when with and the the positive preliminary refractory study relapsed patients anti administered study determine The IMGNXXX and/or with Xb/X venetoclax, and escalation dose to

have identified data continued study further schedule continue for We to dose-limiting toxicity without recommended a triplet X for study. and and at Phase in forward sharing initial We the activity anticipate anti-leukemia well-tolerated evaluation triplet. safety encouraging this of the we IMGNXXX look once observed ASH, profile from the the dosing to a observe combination

AML. that, I monotherapy the We Susan? cover also IMGNXXX evaluate will With to financials. to positive in to turn call our Susan continue residual over as minimal disease

Susan Altschuller

from million with the million expenses to the include from million came revenues. XXXX, in with from were million XXXX. $XXX.X non-cash in remainder Thanks, compared royalty XXXX. expenses $XX.X under $XXX.X Jazz. million results the previously Anna. Starting which G&A Operating comprised milestone compared collaboration year we and with $XX.X generated received which of R&D $XXX.X $XX.X expenses $XXX.X of $XX.X were fee in upfront million revenue, of full fees, license million our million The recognition for coming of

additional In a million. cash million of generating sheet. $XX our of January, $XXX.X on $X.X common incurred costs. balance stock the end, year approximately We with million sold in retention through an we addition, XXXX shares in gross to substantially comprised ended of charge ATM restructuring additional we facility, proceeds million X.X Subsequent

expenses for This cash $XX revenues and guidance operations million, over runway be $XX $XXX Huadong fee XXXX us will million as between requirements Turning amortized clinical half sufficient I end cash between to financial to will equivalents between in revenue portion $XXX fund and of at and $XXX into point be expect million $XXX license second XXXX. million. upfront million guidance supply we year fee and out includes be of that million, assumption million the with to that XXXX, time upfront the to operating $XX delivered. recognized our are from be a Medicine as provides the the will and

of With closing of expects on prior terms call the ImmunoGen based reduce royalty Mark? turn revenues over in half starting for will royalty non-cash for addition, to the Mark the that, transactions In Kadcyla. year to comments. I second this its

Mark Enyedy

Susan. Thanks,

the near first transition strong stage and us our long-term cash a entered resources portfolio position data With we market lead pivotal accelerating first a to an and approval, business. open past second significant company readout pivotal place in after program our bring with oncology as in year generate for the with XX XXXX. months, XX near-term right carry our strong in transformative we and integrated earlier this the a for to program, call team fully With So and we for momentum strategy, XXXX, and prospects to we questions. value a the that, in products to to our will two have important

Operator

first Newman Instructions] comes question from our you. Thank And John Canaccord. [Operator from

Your line is open.

John Newman

morning. Hi, Thanks guys. my for questions. taking Good

quick Just questions have here. two

one, Obviously, you there? a bit. – enrollment you first would is that am Thanks. FORWARD some I demand for The for open difficult whether overenrolled are patient I had additional study believe the if SORAYA to mirvetuximab, I study curious COVID different environment. things for I in previously But the if know and be the just that

Susan Altschuller

John. Thanks,

considered is XX%, that’s really So, about when we the you acceptable upper are I overenrolled which limit FORWARD designs. thinking about study by

worked to benefit, for. the able had more that brisk were at surprised turned question thankfully, XX% the enrollment end patients patients SORAYA be originally and if answer. out MIRASOL. you same and with eligibility to to was set out It because want we the patients we out about enroll I very to met I there had it FORWARD who the occurs all designed You study answer with than to the so were the accommodate criteria that wouldn’t consented and

John Newman

as soon able how for I question be listing, listing to compendia Great. potential mirvetuximab you. second approval monotherapy have combination file compendia compendia might you a mirvetuximab listing? therapy, just And for after the that curious Thanks. Thank regarding

Mark Enyedy

Yes, almost immediately, John.

the required So that the BEV and MIRV into with two peer-reviewed run have journals to is and what’s of expectation publications so cohorts then results and so the is we two included get for basis but submission, the very compendia the work treatment to is guidelines. the move have in quickly following the as to approval that with studies initial those their to expectation use the far

John Newman

Thank you very Okay, much. great.

Operator

Thank you.

comes from Securities. next Our question Michael from Schmidt Guggenheim

Your line is open.

Yige Guo

taking is and This morning. Congrats good Yige Hi, the Michael. for on thanks progress our questions. for

ovarian Avastin Maybe we combo since platinum-agnostic treatment incentive on in step? efficacy care can the of any mirvetuximab. the how at is should could that on to think MIRV isn’t And presented maturity next for population you ASCO? bar question color first inform Our cancer, provide there the this no be

Anna Berkenblit

Yes.

ASCO overall response in year, a patients the plus of as last for Avastin. reminder disease. FR alpha So mirvetuximab cohort the Lucy population, confirmed in platinum-agnostic And presented Gilbert rate platinum-resistant at with was XX% high data

was So these these that in numbers, favorably subset, and populations. Both XXs. the see would of it was recurrence you high compare these subset, in response rate what of to the response care the XX% platinum-sensitive rates the in standard

confirmed response is rate So, XX%. for Avastin chemotherapy, XX%, plus the

plus mirvetuximab to relative looked data the Avastin disease. that nice So, platinum-resistant quite in

typically with prior get disease, response platinum-based Turning just low therapy, you the with a platinum-sensitive doublets in to of recurrent rate one line XXs.

fact quite patients the that platinum-based therapy. XXs the in so nice about to when again are response And you think exposing we rate not our is

give consider And you as options think the some think be expansion. I in as will compendia this So, about to we Mark, will for label the solidifying heard nice meantime, from us listing. the we approach formal really

Yige Guo

And Can you to would frontline XX in Got you patients that of next don’t it. to elaborate potential CR primary this a endpoint words, or then XXX, CRI. the question, you other XX Thanks, of scenario said bar maybe enroll to be cohort? patients the on XX% little you patients or all what to need need in Anna. up clear on you number minimum the enroll the meet

Anna Berkenblit

When as frontline you on would based XX received rate at their point their precedent. a regulatory approval Elzonris in to I patients. that you you they label, look relevant see will full Sure. CR/CRc BPDCN

Yige Guo

for That’s questions. helpful. it. Got That’s our all you Thank much. very

Operator

you. Thank

comes Peaker from question Boris Cowen. next from Our

open. is line Your

Boris Peaker

and morning. just required manufacturing, manufacturing, Good kind And are the wanted specifically submitting any manufactured for are involved? question of what which prior assay studies steps is first to to it where the BLA? companies talk mirvetuximab, ask or you whether about it’s other My to validation doing can

Mark Enyedy

Sure.

So, the components X of each all to ADC with together. the recall bring you to components together an step conjugation those

So and payload Ingelheim, the SAFC, Sigma-Aldrich we for use is steps. the and is produced Boehringer by produced then antibody is by the linker [Indecipherable] the BFT at produced conjugation

of So, we’re in validation good terms for mirvetuximab. shape in

all relevant have We of place. in the assays

BLA ready And so, terms that should in this inspection following in submission we shape for – be time for of facility. we’re good at a the

Boris Peaker

XXX what curious how is of on on compete your if And take in Great. just Elzonris my last to commercially is question with BPDCN. I’m kind approved

Mark Enyedy

of – would Yes. key pharmaceutical We continue to I think on parameters basis the the commercialization. of

efficacy, favor there on data at are the favorably, safety, parameters And that tilt generated to convenience. we’re that quite to the those we to date. it think So, generated label safety particularly we’ve convenience data as to all on their relates going the versus in relevant compare data patient looking and you date, the think based our we’ve today generated based

at infusion. initiate therapy, least with into [indiscernible] the to for outpatient hospital XXX, If patient required days admitted X treatment you is look Elzonris, a at be to

the all be for And think the emerging we quite favorably. those basis that profile we see parameters, would So, will and competition. on compare

Boris Peaker

questions. Great. Thank you for my taking

Operator

you. Thank

Our from from next Blair. William comes Hsieh question Andy

Your open. line is

Andy Hsieh

Great. Thanks my to much very very for and look XXXX. eventful a questions taking forward

So, I couple questions just for in ASCO. have kind Anna of a framing of terms expectations for of

ASCO at XX longer be the So, would this same XX population this follow-up roughly with patient first – off, year?

Anna Berkenblit

Yes, Andy.

with mentioned asked. of we probably PFS the So, Yes, longer following last duration number previous the been combination. when see it’s that to and response period data, what encouraged now year, should remain you will was you about time. shared patients. addition We I ORR will for patients potential in the have quite data same that now of And the a see of question data we’ve which

Andy Hsieh

And do about of had you among Great, Avastin-naive great. Did reminding you believe see Avastin. I who activity there were higher a enrolled? patients XX% XX mind patients efficacy me, previous so the in the

Anna Berkenblit

of kind the use because it also that, Andy, with at we priors. look correlated number of to When tease apart was was hard Avastin

them the data set, small couldn’t given So, apart. you take

Andy Hsieh

I see.

I Okay. catch the makes really And That’s that sense. ISTs, that. – two for didn’t then yes,

that say and – you the progressing did patients as are could those data So say soon? well and XX you you did then patients have XXX

Anna Berkenblit

are So carboplatin. for ISTs mirvetuximab these two plus

We performance the study dose basically Phase X encouraging doublet the have It our expect MIRV, like bevacizumab. escalation you like a for very for looks from data carbo doublet. the would without triplet platinum-based

for MIRV, on this So, those carbo encouraging further of two the exploration basis us with came ideas doublet. to data, of preliminary investigators

Harter Dr. Germany. is first The in

with running. [indiscernible] at standard in and continue setting. getting up really is in setting. back or And they’re sectors to into concept working maintenance this Ohio with recurrent here, study therapy AGL with U.S. plus mirvetuximab run first We’re the came driven doing opportunity randomized MIRV Similarly, Phase that’s that without held to is maintenance the and a for mirvetuximab platinum-based us to State being and platinum-sensitive the X us neoadjuvant frontline at in the several get the carbo,

study And a in patients up and with some running. translational also so, and a and XX getting feasibility science that’s really built correlative is that

can’t regarding I when for the be think will investigators available. data speak I

Andy Hsieh

Okay, you That’s got it. helpful. much. very Thank

Operator

Thank you.

question from from MacKay Capital Kennen RBC next Our Markets. comes

is open. line Your

Kennen MacKay

Hi. the XXXX the first Congrats for would... in taking question. I progress thanks and I on guess,

Mark Enyedy

Kennen. Hi,

Kennen MacKay

about antibody perspective for sort MIRV unmet versus that? the XXX, or or prior just are What back utilized of that strategy secondly, the the your And of returning anticipated Thanks. of a you’ll filing thinking to other half ahead just need full-targeted year to sort IND if wanted you addressing then the about commercial or pre-hiring you’re small build to of in BLA is on of how ahead understand molecules? of thinking understand sort ADCs previously, sort how be the again of

Mark Enyedy

fill on commercial start hand Anna Sure. it over the XXX. then with to planning I’ll

think is Kennen, you patterns targets relatively concentrated physician about a and when market, So, the like. and referral this

support ability manage. And finance well we think our required and robust so, will commercial the that to investment the – be a to within launch

And have so, those the recruiting a benefit at market of more mix, terms research of understanding, these we with are, lining like. would of efforts once post distribution issues. force, with on will agreements move definitive that, developing kinds earnest or our this sales course, segmentation, physician-patient are in patients the the we move in the readout. point payer outside some where we concentrated parallel survey readout, And are to support could goal with how and distribution. of the a In with SORAYA define we we, to that plan. working Again, Again, sales of forward management up vendors approach

of So, year think expenditure the and in spend this these fourth significant for and about planning some of earlier benefit will a as in year, with of expenditures as XXXX. in see through positive readout heavily in ramping certainly the and we anticipation this we then work approval the we the of the filing part some year quarter of exercises the

turn me let follow-up to pause just ask and Anna. over So, if and any there, me it not, I’ll

Kennen MacKay

No, that color. helpful. that’s Thank appreciate you. I really

Anna Berkenblit

is broader FR cell a IMGNXXX, separate next-generation folate really allows on turning of population targeted receptor to events which greater that address which to designed it alpha, by positive topic two So targeting we’ve alpha internalization killing. our we’ve tumors. greater And ADC, Vidaza and FR alpha done epitopes

combination DMXX, more stable is have itself, mirvetuximab. greater payload that allows even for the hydrophobic. stability in a the bit linker And circulation peptide than also We with a

of get the of can bystander you once FR alpha killing, more even the some So expression. help with heterogeneity internalized, is ADC which

are alpha know population FR just with that so the cutoff to that far whom than IMGNXXX in patients cancer, but we generated of cancers premature selection, alpha with not double we about the additional patient types, broader is alpha can So, mirvetuximab, IMGNXXX much little tumors what mind, mirvetuximab. moving know XX% population FR because be positive triple-negative endometrial positive XX% for ovarian thus given we potential really cancer. but data that is ovarian with other This tumors, expression, confident benefit the cancer, for that a for the cancer but XX% alpha indications will those And lower we the the from address preclinical for anticipate and to of expression. have broader lung then appropriate also medium have tumor say actually of breast high expression, the it’s FR we

Kennen MacKay

Thank you.

Operator

you. Thank

next Fye Our comes Jessica from JPMorgan. question from

Your open. line is

Luke Brennan

give on between Jess. coming Luke to of we detail Good of for morning. This this the sort can level idea I XQ of questions. an in is expect year? us readout can for what Thanks data taking our for SORAYA start top you line later versus guess

Anna Berkenblit

now, and and needs response pretty we say Duration rate Little overall for as Luke, by are sufficient time response, data to when have duration endpoint. be. is to better SORAYA, hard response doing because confirmed investigator, our patients you over will which able accurately we mature the to assess right know, will on median primary are of long mirvetuximab of the

And we so material share it. have will when we data,

Luke Brennan

than additional sort And color revenues also, Okay. recognized? than can entire then amortized that those year, shorter guys can we give you expect is licensing fee? to that, any be there totally see follow-on the when we of Should over us on that, longer the

Susan Altschuller

Yes.

in As $XX delivered. on supply license recognized filing, fee will we our mentioned time as be million are over requirements upfront clinical the

XXXX amortized the that be supply revenue plan. our estimated fee the of current based an amount guidance on So, includes will

that be supply which would it’s dependent fee continue of Huadong recognized to plan, be be half could the on its to strategy. again, up regulatory potentially XXXX, will determines estimate refined as Our but the in

Luke Brennan

Alright. Thank you very much.

Operator

from Thank Amin you. from And Biren next Jefferies. our comes question

open. Your is line

Biren Amin

questions. an taking you this more my and I are for by I increase higher has this think just Thanks exposure compound, Maybe in MIRV. half guys. conjugate over hi, think also life IMGNXXX, MIRV one on seeing with XX% than Yes, also

safety year it end? profile with tox in to as you MIRV, particular, XXX ocular the compares the by file So thinking Anna, of are how you maybe about as IND

Anna Berkenblit

Yes.

tubulin-directed the payloads early so it’s again, auristatins with payloads, events tubulin-directed maytansinoids. little ADCs a with are adverse that seen and to So including ocular but speculate, including Abraxane Biren, then and

linked events that that with any anticipate to but regard not adverse IMGNXXX, me clear ocular it’s there in half-life be it’s specifically. will it’s some think reasonable to I to

optimally the do the we the we also how are think that events to support we data I And have need with So, doing mirvetuximab. manage adverse out figured preclinical IND. to ocular to really

we apply and lessons when that. things eye those patient consider of like design in will lubricating we So terms study for drops learned

Biren Amin

And animal studies a as in preclinical with model it of anything your seeing in maybe just XXX relates comparison are you follow-up toxicity? that, to in MIRV just on terms

Anna Berkenblit

this point. at Not

Biren Amin

Great. Thank you.

Operator

you. Thank

Our next question Leerink. from from comes Chang Jonathan SVB

open. Your line is

Jonathan Chang

Good morning and my thanks taking for question.

for potential the one Just may before BLA want results filing and the SORAYA mirvetuximab? given the to about of MIRASOL talk of potentially proximity the the regulators risk me, data that readout, the you can any MIRASOL see if approving

Mark Enyedy

data Yes. the and We SORAYA mean ORR the surpassed would fairly is available get accelerated this that question in approval, readout if positive the the The the of DOR answer regulatory therapy, which for delay for is basis FDA there that is no and this action. criteria often. to this, meets case for

Jonathan Chang

you. Thank it. Got

Mark Enyedy

Great.

Operator

Thank you.

H.C. from comes Ramakanth Wainwright. Swayampakula Our last from question

open. line is Your

Swayampakula Ramakanth

but have taking my and answered, you. for Thank have is your just MIRV my Most you trying commercialization also questions. XXX? to of Europe for both in strategy what – Thank questions been understand

Mark Enyedy

Sure.

these in commercial investments both cases, and certainly we our are so physician again, modest and own meaning something financing. markets could are So the highly undertake with the are limited concentrated that targets

we So, markets. those are evaluating

mirvetuximab. as EU outcome relates the as We for bit little of approval. it to think require will a a the likely time have of basis that We MIRASOL

our support controlled a but probably to results data, will SORAYA want is the approval. they study about randomized them to expectation talk the will of We

commercialized the the year of both revisit will launch robust into XXXX. over in of in we latter ImmunoGen again, could be Europe. and this this course So, a part by support could the we markets products those But of and

Swayampakula Ramakanth

for my Thanks question. Thank you, Mark. taking

Operator

And our Thank Mark that today’s any to question-and-answer closing to over conference. Enyedy conference I’d you. like turn conclude does session for back And the for remarks.

Mark Enyedy

for questions thank this Great. you Well, morning. all the

about around We to we are reporting major our progress in and subsequent the Thanks. and look will data presentations. ahead our calls excited year forward

Operator

Everyone, Ladies wonderful you concludes disconnect. day. your you today’s call. and may conference and now gentlemen, for a participation Thank have this

Immunogen (IMGN) 12 Feb 212020 Q4 Earnings call transcript